The letter requested information including how much Marathon spent to bring the drug to the U.S. market; the company’s profit projections; and its plans to ensure patients can afford the drug. The senators’ letter asked Marathon to detail how much it paid to acquire and analyze the old clinical trial data. Under the Orphan Drug Act, Marathon has seven years to exclusively sell the drug before generics can enter the market. The other signees of Friday’s letter were Sen. Al Franken (D., Minn.), Sen. Cory Booker (D., N.J.), Sen. Elizabeth Warren (D., Mass. ), Sen. Maggie Hassan (D., N.H.), Sen. Sheldon Whitehouse (D., R.I.) and Sen. Tammy Baldwin (D., Wis.).

Source: Wall Street Journal March 05, 2017 22:18 UTC